Skip to main content
. 2021 Jul 21;12(2):390–397. doi: 10.1016/j.jceh.2021.07.004

Table 2.

Histological Findings of the Liver in COVID-19 and Their Correlation With Elevated Liver Enzymes.

Histological parameters All cases (n = 41) Normal AST or ALT N = 8 [I] AST or ALT 1X-2X (n = 18) [II] AST or ALT >2X (n = 14) [III] P value I vs II + III P value
I vs III
Macrovesicular steatosis 29 (70.7%) 8 (100%) 13 (72.2%) 8 (57.1%) 0.080 0.051
 Mild 16 (39%) 3 (37.5%) 8 (44.4%) 5 (35.7%)
 Moderate 11 (26.8%) 5 (62.5%) 4 (22.2%) 2 (14.3%)
 Severe 2 (4.8%) 0 1 (5.5%) 1 (7.1%)
Lobular necroinflammation 10 (24.4%) 0 5 (27.7%) 5 (35.7%) 0.165 0.115
Rare individual apoptosis 8∗ (19.5%) 1 (12.5%) 2 (11.1%) 4 (28.6%) 1.000 0.613
Portal inflammation 13 (31.7%) 2 (25%) 5 (27.7%) 6 (42.8%) 1.000 0.649
 Mild 11 (26.8%) 1 (12.5%) 5 (27.7%) 5 (35.7%)
 Moderate 2 (4.8%) 1 (12.5%) 0 1 (7.1%)
 Severe 0 0 0 0
Fibrosis 8$& 2a (25%) 1b (5.5%) 5c (35.7%) 0.649 1.000
Centrilobular ischemic necrosis 11 (26.8%) 3 (37.5%) 5 (27.7%) 3 (21.4%) 0.660 0.624
Cholestasis (all mild) 17∗ (41.5%) 5 (62.5%) 7 (38.9%) 4 (28.6%) 0.229 0.187
Increased portal vascular channels 24∗ (58.5%) 4 (50%) 10 (55.5%) 9 (64.3%) 0.702 0.661
Sinusoidal microthrombi 5∗ (12.2%) 0 3 (16.6%) 1 (7.1%) 0.565 1.000
Sinusoidal congestion with neutrophil influx 14 (34.1%) 1 (12.5%) 8 (44.4%) 5 (35.7%) 0.221 0.351
Kupffer cell prominence 9∗ (21.9%) 1 (12.5%) 2# (11.1%) 5# (35.7%) 1.000 0.351

AST, aspartate aminotransferase; AST, alanine aminotransferase.

∗AST/ALT value not available in one case; # includes one case with Kupffer hemophagocytosis; $ includes one case of cirrhosis, three cases with stage 3 fibrosis, and four cases with stage 1 fibrosis (Ishak staging system); & excludes three cases of zone 3 pericellular fibrosis; a represents one case with stage 1 fibrosis and one case with stage 3 fibrosis; b represents one case with stage 3 fibrosis; c represents three cases with stage 1 fibrosis, one case with stage 3 fibrosis, and 1 case with cirrhosis.